Oxxon Therapeutics Limited
Patent Owner
Stats
- 3 US PATENTS IN FORCE
- 0 US APPLICATIONS PENDING
- Jun 30, 2011 most recent publication
Details
- 3 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 120 Total Citation Count
- Dec 05, 1994 Earliest Filing
- 15 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
| Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
- No Recent Publications to Display
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2011/0159,034 METHODS AND REAGENTS FOR VACCINATION WHICH GENERATE A CD8 T CELL IMMUNE RESPONSEAbandonedNov 05, 10Jun 30, 11[A61K, A61P]
2010/0119,551 Methods and reagents for vaccination which generate a CD8 T cell immune responseAbandonedJun 19, 09May 13, 10[A61K, A61P]
2009/0324,632 Methods and reagents for vaccination which generate a CD8 T cell immune responseAbandonedMay 15, 09Dec 31, 09[A61K]
2009/0191,237 Methods and reagents for vaccination which generate A CD8 T cell immune responseAbandonedAug 04, 08Jul 30, 09[A61K]
2008/0267,996 Compositions for inducing an immune response against hepatitis BAbandonedNov 20, 07Oct 30, 08[A61K, C12N, A61P]
2004/0213,799 Methods and reagents for vaccination which generate a CD8 T cell immune responseAbandonedOct 16, 03Oct 28, 04[A61K]
2004/0191,272 Methods and reagents for vaccination which generate a CD8 T cell immune responseAbandonedApr 28, 04Sep 30, 04[A61K]
2004/0131,594 Methods and reagents for vaccination which generate a CD8 T cell immune responseAbandonedSep 02, 03Jul 08, 04[A61K]
5972351 Plasmodium falciparum MHC class I-restricted CTL epitopes derived from pre-erythrocytic stage antigensExpiredDec 05, 94Oct 26, 99[A61K]
Top Inventors for This Owner
| Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.
